Loading stock data…
$2.13-0.07 (-2.97%)
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and internationally.
Veru Inc. in the Healthcare sector is trading at $2.17 with a market capitalization of $44M. Wall Street consensus targets $25.67 (3 analysts), implying a +1082.8% move over the next 12 months. The stock is currently near its 52-week low of $2.05, remaining 13.2% below its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 29 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$7.71M↓ | -$7.22M↓ | -$5.42M↑ | -$7.46M↑ | -$8.03M |
| Net Income | -$6.99M↓ | -$2.74M↑ | -$5.33M↓ | $1.45M↑ | -$7.33M |
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and internationally. It provides FC2 fe...